Nanotechnology in interventional cardiology

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 4, Issue 1, 2012, Pages 82-95

  Cyrus, Tillmann ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALLOON ANGIOPLASTY; BIODEGRADABLE STENTS; DRUG ELUTION; FOURTH GENERATION; INTERVENTIONAL CARDIOLOGY; LOCAL DRUG DELIVERY; MOLECULAR TARGETS; NANO PARTICULATES; RESTENOSIS; SIDE EFFECT; STENOSES; STENT DESIGN; VASCULAR WALL;

BIOCOMPATIBILITY; DRUG DELIVERY; MOLECULAR PHYSICS;

NANOTECHNOLOGY;

ANGIOTENSIN[1-7]; AVI 4126; DACTINOMYCIN; DEXAMETHASONE; FIBRINOGEN RECEPTOR ANTAGONIST; GADOLINIUM; HEPARIN; HIGH DENSITY LIPOPROTEIN; INTERCELLULAR ADHESION MOLECULE 1; NANOCARRIER; NANOPARTICLE; PACLITAXEL; RAPAMYCIN; VASCULOTROPIN;

ARTICLE; ATHEROGENESIS; BIOCOMPATIBILITY; CARDIOLOGY; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG HALF LIFE; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; HUMAN; IN-STENT RESTENOSIS; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; STENT THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE;

ANGIOPLASTY, BALLOON, CORONARY; ANIMALS; BIOCOMPATIBLE MATERIALS; CARDIOLOGY; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; NANOTECHNOLOGY;

EID: 83655163899     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.154     Document Type: Article

References (105)

1. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol 1992, 19:267-274.
2. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998, 31:224-230.
3. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
4. Brodie B, Pokharel Y, Fleishman N, Bensimhon A, Kissling G, Hansen C, Milks S, Cooper M, McAlhany C, Stuckey T. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for st-segment elevation myocardial infarction: a 15-year single-center experience. JACC Cardiovasc Interv 2011, 4:30-38.
5. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JGP, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ. 5-Year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute st-segment elevation myocardial infarction: a follow-up study of the passion (paclitaxel-eluting versus conventional stent in myocardial infarction with st-segment elevation) trial. JACC Cardiovasc Interv 2011, 4:24-29.
6. Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, Beatt K, Tirouvanziam A, Polonski L, Stella PR, et al. Four-year follow-up of typhoon (trial to assess the use of the cypher sirolimus-eluting coronary stent in acute myocardial infarction treated with balloon angioplasty). JACC Cardiovasc Interv 2011, 4:14-23.
7. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
8. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M. A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997, 19:1058-1066.
9. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha S-W, Grossmann MP, Gurm H. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based pci: a meta-analysis of randomized controlled trials. EuroIntervention 2009, 5:384-393.
10. Ikeoka D, Vieira C, Lemos P, Strabelli T, da Silva E, Perin M, Groselj-Strele A, Tiran B, Tiran A, Caramelli B. Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting. Clin Res Cardiol 2009, 98:44-51.
11. Lefkovits J, Topol EJ. Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997, 40:141-158.
12. Landzberg BR, Frishman WH, Lerrick K. Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures. Prog Cardiovasc Dis 1997, 39:361-398.
13. Oberhoff M, Kunert W, Herdeg C, Küttner A, Kranzhöfer A, Horch B, Baumbach A, Karsch KR. Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res Cardiol 2001, 96:275-282.
14. Gunn J, Holt CM, Francis SE, Shepherd L, Grohmann M, Newman CMH, Crossman DC, Cumberland DC. The effect of oligonucleotides to c-myb on vascular smooth muscle cell proliferation and neointima formation after porcine coronary angioplasty. Circ Res 1997, 80:520-531.
15. Luo Z, Palasis M, Yamakawa M, Liu LX, Vincent KA, Trudell L, Akita GA, Koch WJ, Cheng SH, Gregory RJ, et al. Catheter-mediated delivery of adenoviral vectors expressing β-adrenergic receptor kinase c-terminus inhibits intimal hyperplasia and luminal stenosis in rabbit iliac arteries. J Gene Med 2004, 6:1061-1068.
16. Chapman G, Lim C, Gammon R, Culp S, Desper J, Bauman R, Swain J, Stack R. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res 1992, 71:27-33.
17. Westedt U, Barbu-Tudoran L, Schaper AK, Kalinowski M, Alfke H, Kissel T. Effects of different application parameters on penetration characteristics and arterial vessel wall integrity after local nanoparticle delivery using a porous balloon catheter. Eur J Pharm Biopharm 2004, 58:161-168.
18. Karanian JW, Peregoy JA, Chiesa OA, Murray TL, Ahn C, Pritchard WF. Efficiency of drug delivery to the coronary arteries in swine is dependent on the route of administration: assessment of luminal, intimal, and adventitial coronary artery and venous delivery methods. J Vasc Interv Radiol 2010, 21:1555-1564.
19. Tepe G, Duda SH, Kalinowski M, Kamenz J, Brehme U, Hanke H, Claussen CD, Bares R, Baumbach A, Dinkelborg LM. Local intra-arterial drug delivery for prevention of restenosis: comparison of the efficiency of delivery of different radiopharmaceuticals through a porous catheter. Invest Radiol 2001, 36:245-249.
20. Westedt U, Barbu-Tudoran L, Schaper A, Kalinowski M, Alfke H, Kissel T. Deposition of nanoparticles in the arterial vessel by porous balloon catheters: localization by confocal laser scanning microscopy and transmission electron microscopy. AAPS J 2002, 4:206-211.
21. Plante S, Dupuis G, Mongeau CJ, Durand P. Porous balloon catheters for local delivery: assessment of vascular damage in a rabbit iliac angioplasty model. J Am Coll Cardiol 1994, 24:820-824.
22. Lambert C, Leone J, Rowland S. Local drug delivery catheters: functional comparison of porous and microporous designs. Coron Artery Dis 1993, 4:469-475.
23. Kipshidze N, Iversen P, Overlie P, Dunlap T, Titus B, Lee D, Moses J, O'Hanley P, Lauer M, Leon MB. First human experience with local delivery of novel antisense avi-4126 with infiltrator catheter in de novo native and restenotic coronary arteries: 6-month clinical and angiographic follow-up from avail study. Cardiovasc Revasc Med 2007, 8:230-235.
24. Nasser TK, Wilensky RL, Mehdi K, March KL. Microparticle deposition in periarterial microvasculature and intramural dissections after porous balloon delivery into atherosclerotic vessels: quantitation and localization by confocal scanning laser microscopy. Am Heart J 1996, 131:892-898.
25. Wilensky R, March KL, Gradus-Pizlo I, Schwauwecker D, Michaels M, Robinson J, Carlson K, Hathaway DR. Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. Am Heart J 1995, 129:852-859.
26. Scheller B, Hehrlein C, Bocksch W, Rutsch W, Haghi D, Dietz U, Bohm M, Speck U. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006, 355: 2113-2124.
27. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, Werner GS, Antoni D, Kleber FX, Bocksch W, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009, 119:2986-2994.
28. Hamm CW. AHA Scientific Sessions 2009, Nov. 14, 2009.
29. Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during pci of small coronary vessels, a prospective randomised clinical trial. The piccoleto study. Heart 2010, 96:1291-1296.
30. Oberhoff M, Herdeg C, Al Ghobainy R, Cetin S, Küttner A, Horch B, Baumbach A, Karsch KR. Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc Interv 2001, 53:562-568.
31. Dommke C, Haase KK, Sueselbeck T, Streitner I, Haghi D, Metz J, Borggrefe M, Herdeg C. Local paclitaxel delivery after coronary stenting in an experimental animal model. Thromb Haemost 2007, 98:674-680.
32. Nef H, Möllmann H, Joseph A, Troidl C, Voss S, Rauch M, Kinscherf R, Vogt A, Weber M, Hamm C, et al. Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-d-glucose. Clin Res Cardiol 2009, 98:355-361.
33. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990, 249:1285-1288.
34. Garg S, Serruys PW. Coronary stents: current status. J Am Coll Cardiol 2010, 56:S1-S42.
35. Togni M, Windecker S, Cocchia R, Wenaweser P, Cook S, Billinger M, Meier B, Hess OM. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol 2005, 46: 231-236.
36. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G, Ligthart JMR, van Essen D, de Feyter PJ, Serruys PW. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 2006, 27: 166-170.
37. Hwang C-W, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001, 104:600-605.
38. Ong ATL, McFadden EP, Regar E, de Jaegere PPT, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (last) events with drug-eluting stents. J Am Coll Cardiol 2005, 45:2088-2092.
39. IAKOVOU I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
40. Collet J-P, Aout M, Alantar A, Coriat P, Napoléon B, Thomas D, Trosini-Desert V, Tucas G, Vicaut É, Montalescot G. Real-life management of dual antiplatelet therapy interruption: the regina survey. Arch Cardiovasc Dis 2009, 102:697-710.
41. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
42. Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the american heart association, american college of cardiology, society for cardiovascular angiography and interventions, american college of surgeons, and american dental association, with representation from the american college of physicians. Circulation 2007, 115:813-818.
43. Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, et al. High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the score randomized trial. J Am Coll Cardiol 2004, 44:1368-1372.
44. Malik N, Gunn J, Shepherd L, Crossman DC, Cumberland DC, Holt CM. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. J Invasive Cardiol 2001, 13: 193-201.
45. Kuiper KKJ, Robinson KA, Chronos NAF, Cui J, Palmer SJ, Nordrehaug JE. Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. Scand Cardiovasc J 1998, 32:261-268.
46. Van der Giessen WJ, Lincoff AM, Schwartz RS, Van Beusekom HMM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94:1690-1697.
47. Garg S, Serruys PW. Coronary stents: looking forward. J Am Coll Cardiol 2010, 56:S43-S78.
48. John MC, Wessely R, Kastrati A, Schomig A, Joner M, Uchihashi M, Crimins J, Lajoie S, Kolodgie FD, Gold HK, et al. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents. JACC Cardiovasc Interv 2008, 1:535-544.
49. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007, 100:S36-S44.
50. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906.
51. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101: 948-954.
52. Targonski PV, Bonetti PO, Pumper GM, Higano ST, Holmes DR Jr, Lerman A. Coronary endothelial dysfunction is associated with an increased risk of cerebrovascular events. Circulation 2003, 107: 2805-2809.
53. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997, 29:808-816.
54. Mehran R, Nikolsky E, Camenzind E, Zelizko M, Kranjec I, Seabra-Gomes R, Negoita M, Slack S, Lotan C. An internet-based registry examining the efficacy of heparin coating in patients undergoing coronary stent implantation. Am Heart J 2005, 150: 1171-1176.
55. Aggarwal RK, Ireland DC, Azrin MA, Ezekowitz MD, De Bono DP, Gershlick AH. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein iib/iiia receptor antibody. Circulation 1996, 94: 3311-3317.
56. Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schömig A, Marco J, et al. Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the action trial. J Am Coll Cardiol 2004, 44:1363-1367.
57. Suzuki T, Kopia G, Hayashi SI, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, et al. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104:1188-1193.
58. Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL, et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis 2002, 13:183-188.
59. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 2004, 63:617-624.
60. Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ. van den Brand M, de Feyter P, Popma JJ. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation 2002, 106:1610-1613.
61. Fajadet J, Morice M-C, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez J-L, Eltchaninoff H, Blanchard D, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the ravel trial. Circulation 2005, 111:1040-1044.
62. van Beusekom HMM, Saia F, Zindler JD, Lemos PA, Hoor SLS-t, van Leeuwen MAH, de Feijter PJ, Serruys PW, van der Giessen WJ. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 2007, 28:974-979.
63. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJM. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005, 45:138-141.
64. Walter DH, Cejna M, Diaz-Sandoval L, Willis S, Kirkwood L, Stratford PW, Tietz AB, Kirchmair R, Silver M, Curry C, et al. Local gene transfer of PHVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 2004, 110:36-45.
65. Weiwei Z, Guangqing C, Yanwei X, Na Z. New approach for local delivery of rapamycin by bioadhesive plga-carbopol nanoparticles. Drug Deliv 2009, 16:15-23.
66. Muro S, Cui X, Gajewski C, Murciano J-C, Muzykantov VR, Koval M. Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress. Am J Physio Cell Physiol 2003, 285:C1339-C1347.
67. Muro S, Gajewski C, Koval M, Muzykantov VR. Icam-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood 2005, 105:650-658.
68. Zhang N, Chittasupho C, Duangrat C, Siahaan TJ, Berkland C. Plga nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem 2007, 19:145-152.
69. Danila D, Partha R, Elrod DB, Lackey M, Casscells SW, Conyers JL. Antibody-labeled liposomes for ct imaging of atherosclerotic plaques. Tex Heart Inst J 2009, 36:393-403.
70. Calderon AJ, Bhowmick T, Leferovich J, Burman B, Pichette B, Muzykantov V, Eckmann DM, Muro S. Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers. J Control Release 2011, 150: 37-44.
71. Nahrendorf M, Jaffer FA, Kelly KA, Sosnovik DE, Aikawa E, Libby P, Weissleder R. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 2006, 114:1504-1511.
72. Garnacho C, Albelda SM, Muzykantov VR, Muro S. Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes. J Control Release 2008, 130:226-233.
73. Banquy X, Leclair Gg, Rabanel J-M, Argaw A, Bouchard J-Fo, Hildgen P, Giasson S. Selectins ligand decorated drug carriers for activated endothelial cell targeting. Bioconjug Chem 2008, 19:2030-2039.
74. Theoharis S, Krueger U, Tan PH, Haskard DO, Weber M, George AJT. Targeting gene delivery to activated vascular endothelium using anti e/p-selectin antibody linked to PAMAM dendrimers. J Immunol Methods 2009, 343:79-90.
75. Namgung R, Singha K, Yu MK, Jon S, Kim YS, Ahn Y, Park I-K, Kim WJ. Hybrid superparamagnetic iron oxide nanoparticle-branched polyethylenimine magnetoplexes for gene transfection of vascular endothelial cells. Biomaterials 2010, 31:4204-4213.
76. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc 2004, 126:16316-16317.
77. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett 2006, 6:2220-2224.
78. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, et al. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett 2008, 8: 3715-3723.
79. Hyafil F, Cornily J-C, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007, 13:636-641.
80. Amirbekian V, Lipinski MJ, Briley-Saebo KC, Amirbekian S, Aguinaldo JGS, Weinreb DB, Vucic E, Frias JC, Hyafil F, Mani V, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. PNAS 2007, 104:961-966.
81. Chorny M, Fishbein I, Yellen BB, Alferiev IS, Bakay M, Ganta S, Adamo R, Amiji M, Friedman G, Levy RJ. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci U S A 2010, 107:8346-8351.
82. Cyrus T, Abendschein DR, Caruthers SD, Harris TD, Glattauer V, Werkmeister JA, Ramshaw JAM, Wickline SA, Lanza GM. Mr three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006, 535: 541.
83. Cyrus T, Zhang H, Allen JS, Williams TA, Hu G, Caruthers SD, Wickline SA, Lanza GM. Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler Thromb Vasc Biol 2008, 107:156281.
84. Wang X-F, Jin P-P, Tong Z, Zhao Y-P, Ding Q-L, Wang D-B, Zhao G-M, Jing-Dai Wang H-L, Ge H-L. Mr molecular imaging of thrombus: Development and application of a gd-based novel contrast agent targeting to p-selectin. Clin Appl Thromb Hemost 2010, 16:177-183.
85. Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J Biomed Mater Res A 2010, 93A:1004-1015.
86. Pan D, Senpan A, Caruthers SD, Williams TA, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem Commun 2009, 3234-3236.
87. Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127.
88. Hajitou A, Trepel M, Lilley CE, Soghomonyan S, Alauddin MM, Marini Iii FC, Restel BH, Ozawa MG, Moya CA, Rangel R, et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125:385-398.
89. Li Y, Yu J, Wang Y, Griffin NM, Long F, Shore S, Oh P, Schnitzer JE. Enhancing identifications of lipid-embedded proteins by mass spectrometry for improved mapping of endothelial plasma membranes in vivo. Mol Cell Proteom 2009, 8:1219-1235.
90. Almenar-Queralt A, Duperray A, Miles LA, Felez J, Altieri DC. Apical topography and modulation of ICAM-1 expression on activated endothelium. Am J Pathol 1995, 147:1278-1288.
91. Dustin M, Rothlein R, Bhan A, Dinarello C, Springer T. Induction by IL 1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986, 137: 245-254.
92. Panes J, Perry MA, Anderson DC, Manning A, Leone B, Cepinskas G, Rosenbloom CL, Miyasaka M, Kvietys PR, Granger DN. Regional differences in constitutive and induced ICAM-1 expression in vivo. Am J Physiol Heart Circ Physiol 1995, 269: H1955-H1964.
93. DeMeester SR, Molinari MA, Shiraishi T, Okabayashi K, Manchester JK, Wick MR, Cooper JD, Patterson GA. Attenuation of rat lung isograft reperfusion injury with a combination of anti-ICAM-1 and anti-β2 integrin monoclonal antibodies. Transplantation 1996, 62:1477-1485.
94. Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J Cell Sci 2003, 116: 1599-1609.
95. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther 2008, 16:1450-1458.
96. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366.
97. Mah C, Fraites JTJ, Zolotukhin I, Song S, Flotte TR, Dobson J, Batich C, Byrne BJ. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther 2002, 6:106-112.
98. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krueger A, Gaensbacher B, Plank C. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Therapy 2009, 9:102-109.
99. Chorny M, Hood E, Levy RJ, Muzykantov VR. Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles. J Control Release 2010, 146:144-151.
100. Cormode DP, Briley-Saebo KC, Mulder WJM, Aguinaldo JGS, Barazza A, Ma Y, Fisher EA, Fayad ZA. An APOA-i mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small 2008, 4: 1437-1444.
101. Feng M, Cai Q, Huang H, Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur J Pharm Biopharm 2008, 68:688-693.
102. Virmani R, Burke AP, Kolodgie FD, Farb A. Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002, 15:439-446.
103. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM. Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther 2005, 3:705-715.
104. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA. Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 2006, 1:321-329.
105. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996, 94:3334-3340.